Purchase Order HT001422P0013
Award Date 1/13/22
Potential Completion Date 1/31/27
Potential Value $368K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20889, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Health Agency awarded a $199,584 firm fixed-price purchase order to Cerus Corporation on January 5, 2024, for the procurement of Intercept Platelet Sets (PN INT2140B). The contract, which extends through September 30, 2028, will be performed at Cerus Corporation's facility in Concord, California. This award represents a continuation of the established relationship between the Defense Health Agency and Cerus Corporation for blood safety technologies, with no set-aside designation...
- The Defense Health Agency awarded Cerus Corporation a firm fixed-price purchase order valued at $367.1K on October 1, 2025, for Cerus Intercept Platelet Processing Sets. The contract, which has no set-aside designation, originated from a sources sought notice posted by Tripler Army Medical Center seeking specialized blood processing equipment utilizing the INTERCEPT Blood System technology. This system employs amotosalen, a photoactive compound that uses UVA illumination to inactivate...
- The Defense Health Agency has awarded Cerus Corporation, a for-profit manufacturer of biomedical products, a $87,166.08 firm fixed price purchase order contract to provide the INTERCEPT Blood System for Platelets. This pathogen reduction technology uses riboflavin and UV light to inactivate viruses, bacteria, protozoa, and contaminating white blood cells in platelet components. The contract, which does not have a set-aside designation, will run through June 18, 2024. Cerus has received over 20...
- The Defense Health Agency awarded a firm fixed-price purchase order to Cerus Corporation on July 1, 2024, with a ceiling value of $106,824 for the supply of Intercept Platelet Small Volume Sets. The contract, which runs through September 1, 2027, supports the U.S. Pacific Command Armed Services Blood Bank Center at the U.S. Naval Hospital Okinawa, Japan, and was awarded on a sole-source basis under Federal Acquisition Regulation 13.106-1(b)(1)(i), reflecting Cerus Corporation's unique...
- Cerus Corporation has been awarded a $218,371.20 firm fixed price purchase order by the Defense Health Agency to provide INT PLATELET SET-SMALL, PART NO INT2130B. The contract has a period of performance through September 30, 2024 with no set-aside designation specified. Cerus is a manufacturer of medical devices and technologies for blood safety and pathogen reduction. Through this contract, Cerus will likely supply its INTERCEPT Blood System platelet pathogen reduction sets, which utilize...
- This is a firm fixed-price purchase order awarded by the Defense Health Agency to Cerus Corporation, a for-profit manufacturer of biomedical products. The $21,955.08 contract is for the maintenance and services of the Cerus INTERCEPT Blood System located at William Beaumont Army Medical Center in Fort Bliss, Texas. The contract has a base period of one year starting on May 1, 2024 and includes two one-year option periods, bringing the potential completion date to April 30, 2027. There was no...
- This is a modification to a federal contract awarded by the Office of the Secretary of Defense to Cerus Corporation, a biomedical products company, for the LYOPHILIZED PATHOGEN REDUCED CRYOPRECIPITATE (LYO-CRYO) MANUFACTURING ADVANCEMENT PROJECT. The contract, which has a ceiling value of $24,967,786.00, is an Other Transaction Agreement with no set-aside designation. The contract supports continued development of the company's INTERCEPT Blood System, a technology that uses riboflavin and...
- This is a $133,640.00 firm fixed price purchase order awarded by the Defense Health Agency to Cerus Corporation, a small business manufacturer of biomedical products. The contract is for the provision of illuminator equipment and related maintenance services, with a completion date of October 24, 2019. Cerus has received over 20 previous federal contracts from agencies including the Department of Defense, Department of Veterans Affairs, and Department of Health and Human Services to provide...
- This is a firm fixed-price purchase order contract awarded by the National Institutes of Health (NIH) Clinical Center to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract is for a Preventative Maintenance Agreement for the INTERCEPT Blood System Illuminators, with a period of performance from July 15, 2025, to July 14, 2026, and a ceiling value of $15,372.00. The contract does not have a set-aside designation. Cerus Corporation is the...
- This federal contract award with ID 75A50124C00046 was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Cerus Corporation, a for-profit manufacturer. The $188,446,002.15 cost-sharing contract is for the license of Cerus' proprietary Pathogen Reduction Technology (PRT) for red blood cell (RBC) components, with the goal of reducing the risk of transfusion-transmitted infections by recognized, emerging, epidemic, and endemic pathogens. This...